Newswise — November 22, 2021 – Critically ill patients with COVID-19 can safely be transported for lifesaving extracorporeal membrane oxygenation (ECMO) therapy – with no increased risk of transmitting COVID-19 transmission to ECMO transport team members following standard precautions, reports a study in the ASAIO Journal, official journal of the American Society for Artificial Internal Organs. The journal is published in the Lippincott portfolio by Wolters Kluwer.

In a large series of COVID-19 patients transported for ECMO, there were no cases of SARS‑CoV‑2 transmission to transport team members, according to the report by Jeffrey Javidfar, MD, of Emory University, Atlanta, and colleagues. "This pandemic and COVID-19 present a particular challenge to ECMO referral centers," Dr. Javidfar comments. "But with thoughtful planning and meticulous execution, patients with acute respiratory distress syndrome secondary to COVID-19 can be remotely cannulated and then transported back to an ECMO center without posing an increased risk to the patient or the transport team."

Experience supports safety of ECMO transport for COVID-19 patients

Extracorporeal membrane oxygenation is a life-sustaining therapy for selected critically ill patients. Like cardiopulmonary bypass during surgery, ECMO takes over the work of the heart and lung—but for a period of days or weeks, rather than just a few hours. Well-established for use in patients with other causes of acute respiratory distress, ECMO provides a chance for survival in a subgroup of patients with severe COVID-19.

Requiring specialized equipment and highly trained professionals, ECMO is mainly provided at large medical centers. Typically, ECMO teams travel to the location where the patient is hospitalized, initiate life support, and transport the patient back to the home hospital for ECMO care. But transporting COVID-19 patients might pose a risk of SARS-CoV2 transmission to ECMO transport team members, as well as a risk of complications and adverse effects to patients.

To assess the safety of ECMO transport, Dr. Javidfar and colleagues reviewed data on 101 adult COVID-19 patients (average age 46 years) transported to five different ECMO hospitals around the world. Most patients were transported by ground (ambulance), but 10 were transported by air. Average travel distance was 40 miles (36 miles by ground and 66 by air) and average transport time was 134 minutes.

Each multidisciplinary ECMO team included physicians, critical care nurses, an ECMO specialist or perfusionist, and a driver or pilot. Team members followed strict Airborne Contact Precautions with Eyewear (ACE) and Personal Protective Equipment (PPE) protocols, including face shield or goggles, N95 or higher respirator or facemask, gloves, and an isolation gown. “Special care was taken to not break ACE and PPE protocol from the time the team came into contact with the patient until they returned to their respective ECMO center,” the researchers write.

The evidence supported the safety of ECMO transport for COVID-19, both for patients and for mobile ECMO team members. None of the patients experienced transport-related complications such as pump failure or problems related to catheters placed for ECMO access.

In addition, "[T]here were zero instances of transport team members contracting COVID-19 [within] 21 days after transport," Dr. Javidfar and colleagues write. That's consistent with previous studies showing that healthcare providers in critical care units are not at increased risk of SARS-CoV2 transmission, compared to the general population.

Patients remained on ECMO for an average of 22 days. Forty-four percent of patients survived to hospital discharge – a rate consistent with the growing experience with ECMO support for severe COVID-19.

The five hospitals contributing to the study were part of the COVID-19 Critical Care Consortium – a global alliance of healthcare professionals and researchers committed to using groundbreaking technology to identify the most effective treatments for the most critically ill COVID-19 patients.

"The COVID-19 Critical Care Consortium is a true global collaboration which has made this research possible," comments senior author Giles Peek, MD, of University of Florida, Gainesville. "Informing clinical practice for clinicians taking care of patients during the COVID-19 pandemic, the Consortium transcends institutional and national boundaries, as exemplified by this paper."

Click here to read “Mobile Extracorporeal Membrane Oxygenation for Covid-19 Does Not Pose Extra Risk to Transport Team“

DOI: 10.1097/MAT.0000000000001602

###

About ASAIO Journal

ASAIO Journal, the official publication of the American Society for Artificial Internal Organs, is in the forefront of artificial organ research and development. On the cutting edge of innovative technology, it features peer-reviewed articles of the highest quality that describe research, development, the most recent advances in the design of artificial organ devices and findings from initial testing. Published in eight issues annually, the ASAIO Journal features state-of-the-art investigations, laboratory and clinical trials, and discussions and opinions from experts around the world.

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit www.wolterskluwer.com, follow us on TwitterFacebookLinkedIn, and YouTube.

SEE ORIGINAL STUDY